Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia
Abstract
The SH2 domain-containing inositol 5'-phosphatase (SHIP) is crucial in hematopoietic development. To evaluate the possible tumor suppressor role of the SHIP gene in myeloid leukemogenesis, we examined primary leukemia cells from 30 acute myeloid leukemia (AML) patients, together with eight myeloid leukemia cell lines. A somatic mutation at codon 684, replacing Val with Glu, was detected in one patient, lying within the signature motif 2, which is the phosphatase active site. The results of an in vitro inositol 5'-phosphatase assay revealed that the mutation reduced catalytic activity of SHIP. Leukemia cells with the mutation showed enhanced Akt phosphorylation following IL-3 stimulation. K562 cells transfected with the mutated SHIP-V684E cDNA showed a growth advantage even at lower serum concentrations and resistance to apoptosis induced by serum deprivation and exposure to etoposide. These results suggest a possible role of the mutated SHIP gene in the development of acute leukemia and chemotherapy resistance through the deregulation of the phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3)/Akt signaling pathway. This is the first report of a mutation in the SHIP gene in any given human cancer, and indicates the need for more attention to be paid to this gene with respect to cancer pathogenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dysfunction of SHIP1 has been associated with a spectrum of diseases, including AD, AML, SLE, RA.
“As such, dysfunction of SHIP1 has been associated with a spectrum of diseases, including Alzheimer’s disease (AD), acute myeloid leukemia (AML) and autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)3–6.”
From INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia (2025) · cites this paper as [4]
SHIP1 is primarily expressed in myeloid cells.
“SHIP1 is primarily expressed in myeloid cells”
From INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia (2025) · cites this paper as [4]
SHIP1 deficiency has been implicated in various diseases of the immune system, such as acute myeloid leukemia (AML) and systemic lupus erythematosus (SLE).
“SHIP1 deficiency has been implicated in various diseases of the immune system, such as acute myeloid leukemia (AML) and systemic lupus erythematosus (SLE)3–5.”
From INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia (2025) · cites this paper as [4]
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works
Liu, Q., Sasaki, T., Kozieradzki, I., Wakeham, A., Itie, A., Dumont, D. J., & Penninger, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.7.786 · Cited by 341 · see citing works
Structure, function, and biology of SHIP proteins
Rohrschneider, L. R., Fuller, J. F., Wolf, I., Liu, Y., & Lucas, D. M. (2000) · Genes & Development · doi:10.1101/gad.14.5.505 · Cited by 294 · see citing works
Ware, M., Rosten, P., Damen, J., Liu, L., Humphries, R., & Krystal, G. (1996) · Blood · doi:10.1182/blood.v88.8.2833.bloodjournal8882833 · Cited by 96 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826 · see citing works
INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia
Terzioglu, G., Karp, E. S., Heuer, S. E., Chadarevian, J. P., Ahsan, F. M., Haage, V. C., Davtyan, H., Fogo, G. M., Curle, A. J., Ashour, N., et al. (2025) · doi:10.1101/2025.10.27.684632 · Cited by 3 · see citing works
- Authors
- Luo, J.-M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., Naoe, T., Akao, Y., Ohno, R., & Ohnishi, K.
- Affiliations
- Hamamatsu University School of Medicine (JP)
- Institute of Applied Biochemistry (JP)
- Nagoya City University (JP)
- Nagoya University (JP)
- Aichi Cancer Center Hospital (JP)
- Venue
- Leukemia
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2026168267
- Cited by
- 127
- References
- 4
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 6 · 2021: 4 · 2020: 2 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 2 · 2012: 14
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- ships, acute myeloid leukemia, dominant negative mutation, tumor suppressor, Akt phosphorylation, PI3K/Akt signaling, chemoresistance, apoptosis resistance, etoposide, interleukin-3, K562 cells, somatic mutations
- MeSH terms
- Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Acute Disease, Animals, Antineoplastic Agents, Phytogenic, Chlorocebus aethiops, Etoposide, Genes, Dominant, Humans, Interleukin-3, Leukemia, Myeloid, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Transfection, Tumor Cells, Cultured, Case-Control Studies, Apoptosis, src Homology Domains, Drug Resistance, Neoplasm, COS Cells, Phosphatidylinositol 3-Kinases, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review